LAST UPDATED: May 28, 2021, 4:46 p.m.
New Delhi (Anish Yande): Shares of Sun Pharma fell by over 3 per cent on Friday’s trading session following the announcement of results for the March quarter of 2021. Sun Pharma shares opened at Rs 694 per share from its previous close of Rs 699.50 per share on Wednesday. The shares of the pharma company rose to an intraday high of Rs 694.50 per share before declining to Rs 670.
Sun Pharma net profit rises to Rs 894 crore:
Sun Pharma reported a consolidated net profit of Rs 399.8 crore in Q4 FY20. The pharmaceutical company’s consolidated net profit increased to Rs 894 crore in the January-March quarter of FY21. The company’s net profit increased by 123 percent on a year-on-year basis.
The adjusted net profit of the pharma company is recorded at Rs 1,343 crore in the March 2021 quarter, up 103 per cent year-on-year. For the full year 2020-21, Sun Pharma has reported a net profit of Rs 2,903 crore. The pharma company’s net profit decreased by 23 percent on a yearly basis.
The revenue from operations of Sun Pharma was at Rs 8,184 crore in the March quarter of FY20. The pharma company’s revenue from operations rose to Rs 8,522 crore in Q4FY21, at an increase of 4 percent on a year-on-year basis.
Sales of Sun Pharma up by 12 percent:
India sales of the pharma company grew to Rs 2,670 crore during the March quarter of FY21, increasing by 12.9 per cent. In the financial year 2021, sales in India are at Rs. 1,034 crores, up by 6.5% as compared to the same period last year.
Earnings before interest, tax, depreciation and amortisation (EBITDA) was recorded at Rs 1,956 crore, increasing by 55.8 per cent over last year. The EBITDA margin is recorded at 23.2 per cent.
Sun Pharma’s sales in the March quarter of 2021 grew to $192 million, increasing by 2.8 per cent. The sales in the rest of the world rose to $163 million, rising by 5.5 per cent. The board of directors of Sun Pharma has declared a final dividend of Rs 2 per share for the financial year ended March 2021.
Image Credit: Google